| Objective: To observe the clinical efficacy of anticancer analgesic cataplasm in the treatment of moderate and severe cancer pain through clinical completely randomized grouping principle,so as to provide clinical basis for the improvement of cancer pain and quality of life of patients with anticancer analgesic cataplasm.Methods: According to the complete randomized grouping method,60 inpatients who met the inclusion criteria were divided into two groups at random,which are the experimental group and the control group,30 in each group.Before treatment,there were no significant differences in general data,pain degree,NRS score,onset time of analgesia,QOL score and KPS score between the two groups.After admission,The control group has been treated with oral oxycodone hydrochloride sustained-release tablets + placebo for 10 days,while the experimental group has been treated with oral oxycodone hydrochloride sustained-release tablets + anticancer analgesic cataplasm for 10 days.NRS scores before and after treatment,analgesic onset time,KPS scores,QOL scores and safety of patients in the two groups were truthfully recorded.Intra-group comparisons before and after treatment and inter-group comparisons after treatment were conducted to analyze their statistical significance and compare the comprehensive clinical efficacy of the two groups to judge the efficacy of anticancer analgesic barbs.Result:(1)The onset time of analgesia: After treatment,the onset time of analgesia in the experimental group was significantly better than that in the control group(P=0.0089<0.05);By comparing the two groups before and after treatment--the experimental group P=0.002(P<0.05)and the control group P=0.092(P>0.05);it suggested that the experimental group could significantly shorten the onset time of analgesia,while the control group had no significant change in the onset time of analgesia.(2)NRS score: Before and after treatment,two groups were compared in the group,both groups had statistical significance P=0.000(P<0.05);after treatment,there was no significant difference between the two groups,that is,P>0.05,indicating that both groups can alleviate pain.But there was no significant difference between the two groups.(3)KPS score : There was a significant difference between the two groups after treatment(P=0.003<0.01).Comparing the two groups,the score of the experimental group after treatment was significantly better than that before treatment,suggesting that the experimental group can effectively improve the physical condition of patients.(4)QOL score: After treatment,the QOL score of the two groups had a high statistical significance P=0.000(P<0.05),which was comparable.The difference analysis before and after treatment showed that the experimental group had statistical significance P =0.016a(P<0.05),while the control group had no statistical significance P = 0.516(P >0.05);there is a better improvement of life quality in the experimental group than that of the control group before and after treatment.(5)Pain relief rate: Pain relief of the two groups after treatment was statistically significant P=0.026(P<0.05);pain relief degree of 30 patients in the experimental group was 60.0%,and that of 29 patients in the control group was 31.0%.The comparison between the two groups indicated that the effective rate of patients in the treatment group was higher than that in the control group.(6)Safety: In the course of the study,nausea,vomiting,constipation,sleepiness and other analgesic symptoms occurred in both groups,and there were no obvious differences between the two groups.No significant organ damage and other adverse reactions caused by the drug were observed.Conclusion: Anti-cancer analgesic cataplasm,as a new type of external dosage form,has the advantages of higher curative effect,faster onset,safer and more convenient,and can significantly improve the quality of life of patients,so that patients have better compliance with treatment and higher satisfaction.It is worthy of further clinical application. |
PDF Full Text Request